SPIDAR: Screening Paradigm to Identify Drug Analgesic Response

When profiling lead compounds in discovery programs, gaining early functional insight into pain‑related pathways can provide critical information well beyond dedicated pain indications.

SPIDAR is a unique in vivo screening platform designed to rapidly and cost‑effectively explore analgesic‑related activity across multiple validated pain states, offering early visibility into how compounds interact with key central nervous system mechanisms.

Whether R&D programs are directly targeting pain, or are developed for non‑pain CNS indications sharing biological features with established pain pathways, SPIDAR enables the generation of a clear and interpretable analgesic fingerprint. This early pharmacological profile supports robust GO / NO‑GO decisions, helping teams prioritize, reposition, or discontinue compounds before committing to time‑consuming and fully powered studies.

Accelerating pain and CNS drug discovery with decision‑ready in vivo data

SPIDAR is an innovative in vivo screening platform developed by Transpharmation to rapidly assess the analgesic‑related activity of test compounds across multiple clinically relevant pain states.

By combining validated rodent pain models with integrated behavioral safety assessment, SPIDAR delivers a clear, visual, and easy‑to‑interpret analgesic fingerprint, enabling confident GO / NO‑GO decisions at the earliest stages of drug discovery.

The challenge of early pain drug discovery

Developing new analgesics — and understanding pain‑related effects in CNS programs — remains one of the most complex and failure‑prone areas in drug discovery.

Early programs frequently face:

• High costs associated with fully powered in vivo studies
• Long timelines when compounds are tested model by model
• Limited insight from isolated pain assays
• Late identification of inefficacy or CNS liabilities

SPIDAR was specifically designed to address these issues by delivering broad, early, and actionable pharmacological insight within a single, coordinated screening strategy.

What is SPIDAR?

SPIDAR is a parallel in vivo screening approach that evaluates compound activity across several pain dimensions within a standardized and streamlined study design.

It supports:

• Rapid analgesic profiling of novel molecules
• Early validation of mechanisms of action
• Lead prioritization and candidate selection
• Opportunistic evaluation of non‑pain CNS compounds

SPIDAR acts as a strategic bridge between exploratory discovery and focused, fully powered confirmatory studies.

A comprehensive pain model panel

SPIDAR integrates a panel of validated rodent pain models, executed in parallel, to explore activity across key pain domains, including:

• Acute and tonic pain
• Inflammatory pain
• Neuropathic pain
• Post‑operative pain
• Osteoarthritis pain

This multidimensional approach clarifies where a compound demonstrates meaningful activity, where it does not, and how selective and relevant its analgesic profile may be.

Your result: a clear analgesic fingerprint

The primary output of SPIDAR is a visual analgesic fingerprint summarizing compound activity across pain states.

This fingerprint:

• Highlights relative efficacy across pain domains
• Enables comparison to historical reference compounds
• Integrates behavioral and CNS tolerability information

The result is a decision‑ready pharmacological profile that can be immediately leveraged by discovery teams, program leaders, and external stakeholders.

Integrated behavioral safety assessment

False‑positive analgesic signals are common in pain research due to sedation, motor impairment, or CNS effects.

SPIDAR integrates early behavioral safety assessment, helping to:

• Identify CNS or behavioral liabilities
• Differentiate true analgesia from non‑specific effects
• Increase confidence in early efficacy signals
• This integrated view significantly reduces the risk of advancing compounds based on misleading readouts.

Designed for early discovery constraints

SPIDAR is optimized for early discovery environments, where speed, compound availability, and decision quality are critical.

Key features include:

• Small group sizes
• Limited compound requirement
• Single‑dose screening format
• Rapid turnaround from dosing to final report
• Alignment with 3Rs principles

This makes SPIDAR particularly well suited for lead discovery, early optimization, and portfolio triage.

Translationally anchored and validated

SPIDAR has been validated using clinically established reference compounds across multiple pharmacological classes.

This benchmarking framework strengthens:

• Mechanistic interpretation
• Cross‑compound comparisons
• Early assessment of translational relevance

A simple two‑step development strategy

Step 1 – SPIDAR Screening

Rapid generation of an analgesic fingerprint to guide early GO / NO‑GO decisions.

Step 2 – Confirmatory Studies

Focused, fully powered studies in the most relevant pain model(s) identified by SPIDAR.

This strategy helps optimize resource allocation and accelerate progression toward later‑stage development.

Predictable scheduling and rapid reporting

SPIDAR runs in scheduled sessions throughout the year, enabling predictable integration into discovery timelines.

Results are delivered rapidly, allowing teams to move quickly from data generation to strategic decisions.

Why choose SPIDAR with Transpharmation?

• Multi‑model pain screening within a single, integrated platform
• Early behavioral safety assessment built into the design
• Clear, visual, and decision‑oriented outputs
• Experienced scientific teams and validated models
• Applicable to both pain and non‑pain CNS programs

SPIDAR enables earlier, better‑informed decisions — when they matter most.

Get in touch

Our scientific and business development teams would be pleased to discuss how SPIDAR can support your specific discovery program.